<html xmlns="http://www.w3.org/1999/xhtml" xmlns="http://www.w3.org/1999/xhtml">
 <head xmlns="http://www.w3.org/1999/xhtml">
 <title xmlns="http://www.w3.org/1999/xhtml"></title>
 </head>
 <body xmlns="http://www.w3.org/1999/xhtml">
 
 Philip Morris International Inc. ("PMI") (NYSE / Euronext Paris: PM) 
 submitted a Premarket Tobacco Product Application (PMTA) for its 
 Electronically Heated Tobacco Product (EHTP) to the US Food and Drug 
 Administration's (FDA) Center for Tobacco Products. This is consistent 
 with the Company's stated goal of submitting its PMTA in the first 
 Quarter of 2017.
 
 
 PMI's PMTA seeks authorization to commercialize the EHTP in the United 
 States. Should FDA grant the requested marketing order, Altria Group 
 Inc. would be responsible for commercializing and marketing the product 
 in the United States under the terms of a licensing agreement with PMI.
 
 
 Note to editor
 
 
 On December 5, 2016, PMI submitted a Modified Risk Tobacco Product 
 (MRTP) application for its EHTP to the FDA. Administrative review of 
 that application is ongoing. A PMTA marketing order is a prerequisite to 
 commercializing a new tobacco product such as PMI's EHTP. A decision on 
 the PMTA would allow the marketing of PMI's EHTP without modified risk 
 claims independent of a decision on the MRTPA.
 
 
 Philip Morris International Inc.
 
 
 Philip Morris International Inc. (PMI) is the world's leading 
 international tobacco company, with six of the world&#39;s top 15 
 international brands and products sold in more than 180 markets. In 
 addition to the manufacture and sale of cigarettes, including Marlboro, 
 the number one global cigarette brand, and other tobacco products, PMI 
 is engaged in the development and commercialization of Reduced-Risk 
 Products (RRPs). RRPs is the term PMI uses to refer to products that 
 present, are likely to present, or have the potential to present less 
 risk of harm to smokers who switch to these products versus continued 
 smoking. Through multidisciplinary capabilities in product development, 
 state-of-the-art facilities, and industry-leading scientific 
 substantiation, PMI aims to provide an RRP portfolio that meets a broad 
 spectrum of adult smoker preferences and rigorous regulatory 
 requirements. For more information, see <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.pmi.com&amp;esheet=51534619&amp;newsitemid=20170331005528&amp;lan=en-US&amp;anchor=www.pmi.com&amp;index=1&amp;md5=c50dde9e2d6106c0734b155776ac1d85" rel="nofollow" rel="nofollow">www.pmi.com</a> 
 and <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.pmiscience.com&amp;esheet=51534619&amp;newsitemid=20170331005528&amp;lan=en-US&amp;anchor=www.pmiscience.com&amp;index=2&amp;md5=5f2451999b5e4392a47bcbfc9ada3116" rel="nofollow" rel="nofollow">www.pmiscience.com</a>
 
 
 
 <img xmlns="http://www.w3.org/1999/xhtml" alt="" src="http://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20170331005528r1&amp;sid=benz2&amp;distro=nx&amp;lang=en"></img>View source version on businesswire.com: <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.businesswire.com/news/home/20170331005528/en/" rel="nofollow" rel="nofollow">http://www.businesswire.com/news/home/20170331005528/en/</a></body></html>

Press Releases

Philip Morris International (PMI) Files Premarket Tobacco Product Application for its Electronically Heated Tobacco Product (EHTP) with the US Food and Drug Administration (FDA) - Philip Morris Intl (NYSE:PM)

Philip Morris Intl

Philip Morris International (PMI) Files Premarket Tobacco Product Application for its Electronically Heated Tobacco Product (EHTP) with the US Food and Drug Administration (FDA)



A one-time dose of BEQVEZ has reduced bleeds post-treatment compared to standard of care with a median of zero bleeds (range 0 to 19) after up to three years of follow-up, providing sustained bleed protection and

U.S. FDA Approves Pfizer&#39;s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B


Successfully Executing Strategic Initiatives To Reduce Costs and Preserve Long-term Flexibility


GrafTech International Ltd. (NYSE:EAF) (&#34;GrafTech,&#34; the &#34;Company,&#34; &#34;we,&#34; or &#34;our&#34;) today

GrafTech Reports First Quarter 2024 Results


Long-term Profitable Growth Strategy Driving a More Aerospace Oriented Business


Comparisons are year-over-year unless noted otherwise


First Quarter 2024:



Sales of $431 million, up 28%; Organic Sales up

Barnes Reports First Quarter 2024 Financial Results

CVEO


First Quarter Highlights include:



Reported revenues of $166.1 million, net loss of $5.1 million and operating cash flow of $6.0 million;




Delivered Adjusted EBITDA of $17.3 million and free cash flow of $7.2

Civeo Reports First Quarter 2024 Results


U.S. clean energy incentives revitalize American manufacturing at JM Steel historic manufacturing facility in Pittsburgh, achieving 4 GW of Nextracker-dedicated annualized capacity


Nextracker (NASDAQ:NXT), a global

Nextracker and JENNMAR Subsidiary JM Steel Bolster U.S. Supply Chain with New Facility Expansion to Triple Capacity for Solar Energy Projects



Generated strong first-quarter earnings of $8.2 billion and $14.7 billion of cash flow from operating activities




Achieved quarterly gross production of more than 600,000 oil-equivalent barrels per day in Guyana and